Although HPβCD did not reduce acute infarct size or plasma NfL, its modulation of lipid metabolism and inflammatory mediators positions it as a therapy that shapes the subacute and chronic injury environments, highlighting its potential for biomarker-guided translation to human stroke studies. The gene discussed is NEFL; the disease is Stroke.